COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Conditions: Hypertrophic Cardiomyopathy (HCM)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 331

Sponsor: Bristol-Myers Squibb

Location: IQVIA Durham North Carolina

Summary

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Eligibility Criteria

Inclusion Criteria: * Source Cohort \- Have at least one recorded encounter with a Hypertrophic Cardiomyopathy (HCM) diagnosis during or after 2018 (the first is defined as the index) and aged ≥18 years on the index date. \- Disease-specific patient history documented in the medical record. * HCM Sub-Cohort \- Participants in the source cohort with a known HCM diagnosis * Mavacamten Sub-Cohort - Participants who have their first mavacamten prescription after the index date Exclusion Criteria: • HCM Sub-Cohort \- HCM phenocopy (athlete's heart, hypertensive heart disease, Fabry disease, Pompe disease, Danon disease, amyloidosis) observed after the first observed HCM-associated encounter in the medical record.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06372457). StuddyBuddy aggregates publicly available trial information.